Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Redhill Biopharma Ltd., a foreign private issuer based in Tel Aviv, Israel, on February 23, 2017. The filing covers the month of February 2017 and serves to announce the availability of the Company's Annual Report on Form 20-F via its website.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts solely as a notice of the availability of the Annual Report, which contains the detailed financial data.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing. The document incorporates by reference a press release regarding the publication of the Annual Report.
Guidance, Outlook, and Risks
This filing does not contain management commentary, forward-looking guidance, risk factors, or contingencies. Investors are directed to the Annual Report on Form 20-F for such information.
Key Facts for Investor Verification
- The Company has made its Annual Report on Form 20-F available on its website.
- This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (filed May 2, 2013, and October 29, 2015) and Form F-3 (filed February 25, 2016).
- Dr. Dror Ben-Asher, Chief Executive Officer, signed the report on behalf of the registrant.
- Specific financial figures for the period are not included in this text and must be sourced from the referenced Form 20-F.